Baird Maintains Cencora(COR.US) With Buy Rating, Cuts Target Price to $283
A Quick Look at Today's Ratings for Cencora(COR.US), With a Forecast Between $249 to $283
Cencora Is Maintained at Outperform by Baird
Cencora Analyst Ratings
Cencora's Resilience Amid Challenges Spurs Buy Rating and Positive Growth Outlook
Cencora (COR) Gets a Buy From Barclays
Evercore ISI Adjusts Price Target on Cencora to $270 From $260
Cencora Analyst Ratings
JPMorgan Adjusts Price Target on Cencora to $287 From $280, Maintains Overweight Rating
Evercore ISI Adjusts Price Target on Cencora to $260 From $270, Maintains Outperform Rating
Argus Research Keeps Their Buy Rating on Cencora (COR)
A Quick Look at Today's Ratings for Cencora(COR.US), With a Forecast Between $242 to $287
Evercore ISI Adjusts Price Target on Cencora to $270 From $260
Analysts Conflicted on These Healthcare Names: Cencora (COR), Schrodinger (SDGR) and Biogen (BIIB)
A Quick Look at Today's Ratings for Cencora(COR.US), With a Forecast Between $249 to $287
Cencora Price Target Raised to $287.00/Share From $285.00 by Baird
Cencora Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Raffles Medical Group (OtherRAFLF), Cencora (COR) and Acadia Healthcare (ACHC)
Cencora's Resilient Growth and Strong Walgreens Alliance Affirm Buy Rating
Citigroup Adjusts Price Target on Cencora to $284 From $280